Posted by Michael Wonder on 23 Sep 2025
MavriX Bio receives FDA fast track designation for MVX-220 for treatment of Angelman syndrome
22 September 2025 - MavriX Bio today announced that the US FDA has granted fast track designation for MVX-220, an investigational adeno-associated virus gene therapy for the treatment of Angel,man syndrome.
In May 2025, MavriX announced that FDA had cleared the investigational new drug application for MVX-220.
